Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $722,347 - $1.34 Million
-23,738 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $1.1 Million - $1.63 Million
23,738 New
23,738 $1.45 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Natixis Investment Managers International Portfolio

Follow Natixis Investment Managers International and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

News

Stay updated on Natixis Investment Managers International with notifications on news.